Cellerant Therapeutics Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Out of Business

Cellerant Therapeutics General Information

Description

Developer of cellular and antibody therapies designed to treat hematologic malignancies and other blood-related disorders. The company's therapies use a hematopoietic stem cell-based mechanism for the treatment of cancers and autoimmune diseases, enabling physicians to treat multiple myeloma and myelodysplastic syndrome in an enhanced way.

Contact Information

Formerly Known As
Celtrans
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 39899 Balentine Drive
  • Suite 200
  • Newark, CA 94560
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 39899 Balentine Drive
  • Suite 200
  • Newark, CA 94560
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cellerant Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Out of Business 02-Apr-2024 Completed Out of Business
14. Later Stage VC 12-Feb-2019 Completed Clinical Trials - Phase 3
13. Secondary Transaction - Private Completed Pre-Clinical Trials
12. Grant 22-Aug-2017 Completed Pre-Clinical Trials
11. Debt - General 01-Feb-2015 Completed Pre-Clinical Trials
10. Grant 11-Sep-2014 Completed Pre-Clinical Trials
9. Grant 08-Oct-2012 Completed Pre-Clinical Trials
8. Later Stage VC (Series BB) 21-Sep-2012 Completed Pre-Clinical Trials
7. Later Stage VC (Series BB) 25-Apr-2011 $2.02M $55.5M Completed Pre-Clinical Trials
6. Later Stage VC (Series AA) 09-Feb-2010 $9M $53.5M Completed Pre-Clinical Trials
To view Cellerant Therapeutics’s complete valuation and funding history, request access »

Cellerant Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series BB
Series AA
To view Cellerant Therapeutics’s complete cap table history, request access »

Cellerant Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cellular and antibody therapies designed to treat hematologic malignancies and other blood-related disorder
Drug Discovery
Newark, CA
4 As of 2023

Madison, WI
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cellerant Therapeutics Competitors (95)

One of Cellerant Therapeutics’s 95 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Madison, WI
Cogent Biosciences Formerly VC-backed Waltham, MA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Light Chain Bioscience Formerly PE-Backed Geneva, Switzerland
Aronora Venture Capital-Backed Portland, OR
You’re viewing 5 of 95 competitors. Get the full list »

Cellerant Therapeutics Patents

Cellerant Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021055985-A1 Ipsc-derived, hypoimmunogenic, myeloid progenitor cells Inactive 22-Sep-2019
WO-2021055985-A8 Ipsc-derived, hypoimmunogenic, myeloid progenitor cells Inactive 22-Sep-2019
WO-2018071910-A2 Anti-il1-rap antibodies Inactive 16-Oct-2016
WO-2018071910-A3 Anti-il1-rap antibodies Inactive 16-Oct-2016
AU-2017343565-A1 Isoquinolidinobenzodiazepine (iqb)-1(chloromethyl)-2,3-dihydro-1h-benzo[e]indole (cbi) dimers Inactive 10-Oct-2016 A61K31/5513
To view Cellerant Therapeutics’s complete patent history, request access »

Cellerant Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cellerant Therapeutics FAQs

  • When was Cellerant Therapeutics founded?

    Cellerant Therapeutics was founded in 2003.

  • Where is Cellerant Therapeutics headquartered?

    Cellerant Therapeutics is headquartered in Newark, CA.

  • What is the size of Cellerant Therapeutics?

    Cellerant Therapeutics has 4 total employees.

  • What industry is Cellerant Therapeutics in?

    Cellerant Therapeutics’s primary industry is Drug Discovery.

  • Is Cellerant Therapeutics a private or public company?

    Cellerant Therapeutics is a Private company.

  • What is Cellerant Therapeutics’s current revenue?

    The current revenue for Cellerant Therapeutics is .

  • How much funding has Cellerant Therapeutics raised over time?

    Cellerant Therapeutics has raised $74.4M.

  • Who are Cellerant Therapeutics’s competitors?

    Centrose, Cogent Biosciences, Inovio Pharmaceuticals, Light Chain Bioscience, and Aronora are some of the 95 competitors of Cellerant Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process